multiple myeloma
Conditions
Interventions
Sponsors
The First Affiliated Hospital, Sun Yat-Sen University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years. 2. Relapsed/refractory MM according to the updated IMWG diagnostic criteria 2014 requiring treatment. 3. Patients who has received standard anti-myeloma therapy in the past and evaluated as progression or recurrence. 4. EGCO 0-3. 5. Estimated survival times over 6 months. 6. Meet all of the following blood criteria within 14 days before therapy: a. Total bilirubin <= 3 x upper limit of normal (ULN). b. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) <= 3 x ULN. 7. Meet the pregnancy prevention requirements: not of childbearing potential or agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug. 8. Able to provide written informed consent.
Exclusion criteria
Exclusion criteria: 1. Received other clinical trials for multiple myeloma within three months. 2. Prior or concurrent invasive malignancies. 3. Active systemic infection or any other medical or psychiatric condition which, in the opinion of the investigator, contraindicates the participant's participation in this study. 4. Woman in lactation or preganancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| response rate;toxicity; | — |
Countries
China
Contacts
Public ContactJuan Li
The First Affiliated Hospital, Sun Yat-Sen University
Outcome results
None listed